TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

ASPIRO

Infectious DiseaseDermatologyCardiovascular
Generics

ASPIRO is a generic drug manufacturer focused on Infectious Disease, Dermatology, Cardiovascular. Key products include VORICONAZOLE.

2020
Since
26
Drugs
-
Trials
429
Approved (2yr)

Key Drugs

No active drugs

Recent Activity

DOXYCYCLINE HYCLATE 2026-02-19
OLANZAPINE 2026-02-09
Labeling
OLANZAPINE 2026-02-09
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
DOXYCYCLINE HYCLATE 2026-02-06
Labeling
BUMETANIDE 2026-02-05
SELENIOUS ACID 2026-02-03
DAPTOMYCIN 2026-01-30
Labeling
LACOSAMIDE 2026-01-29
DAPTOMYCIN 2026-01-26
Labeling
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 40%
4 drugs
Dermatology 20%
2 drugs
Cardiovascular 20%
2 drugs
Neurology 10%
1 drugs
Gastroenterology 10%
1 drugs

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Infectious Disease, Dermatology, Gastroenterology
APOTHECON specialty
Infectious Disease, Dermatology, Cardiovascular, Gastroenterology
Baxter specialty
Infectious Disease, Cardiovascular, Dermatology
LEDERLE big-pharma
Infectious Disease, Cardiovascular, Neurology, Dermatology
PAI HOLDINGS PHARM big-pharma
Dermatology, Infectious Disease, Neurology, Cardiovascular